Personalized Medicine Program

R. David Anderson, M.D., and Julie Johnson, Pharm.D.

R. David Anderson, M.D., and Julie A. Johnson, Pharm.D., review an alert that appears in a cardiac patient’s electronic medical record when genetic results suggest a prescribed drug may not be effective. (Photo by Jesse Jones/UF)

Part of the UF CTSI, the UF Health Personalized Medicine Program partners with health professionals and patients at UF Health and across the state to develop, implement, study and refine methods that allow genetic information to be used as a routine part of patient care. The program’s initial focus is on pharmacogenetics.

The program is led by faculty from the UF College of Pharmacy and brings together a large and multidisciplinary team that provides the complementary clinical, informatics, laboratory medicine, and administrative expertise required to implement genomic medicine.

Created in June 2011 under the leadership of Julie A. Johnson, Pharm.D., the program dedicated its first year to developing the complex clinical, laboratory and information flows required for UF Health to systematically implement genomic medicine. The program’s first clinical implementation launched in June 2012, and the program continues to build on this infrastructure through multi-faceted patient care, education and research initiatives.

Learn more about the program’s clinical implementations, education programs, research, publications and news on the program’s website at http://personalizedmedicine.ufhealth.org.

Program Contact & Team

Amanda Elsey, MHA, Program Manager
352-273-6257, aelsey@cop.ufl.edu

UF Health Personalized Medicine Program Team

Program Milestones

  • Jun 2011: UF Health receives two grants from the National Institutes of Health to support the creation and launch of a new Personalized Medicine Program led by the UF CTSI:
  • Jun 2012: Program launches at UF Health Shands Hospital, which incorporates a simple blood test for interventional cardiology patients that provides genetic information indicating how an individual will likely respond to clopidogrel, an anticlotting drug commonly prescribed following treatment in the catheterization lab for blocked heart vessels
  • Oct 2012: Program launches ongoing research study to test feasibility of preemptive genotyping
  • Jun 2013: UF Health receives a four-year grant of $3.7 million to expand the program as part of the Implementing Genomics in Practice (IGNITE) Network, which is led by the NIH’s National Human Genome Research Institute and supports a network of projects at Duke University and Mount Sinai plus a coordinating center at the University of Pennsylvania